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AbstrACt
Introduction Chronic non-malignant pain has a major 
impact on the well-being, mood and productivity of 
those affected. Opioids are increasingly prescribed to 
manage this type of pain, but with a risk of other disabling 
symptoms, when their effectiveness has been questioned. 
This trial is designed to implement and evaluate a patient-
centred intervention targeting withdrawal of strong opioids 
in people with chronic pain.
Methods and analysis A pragmatic, multicentre, 
randomised controlled trial will assess the clinical and 
cost-effectiveness of a group-based multicomponent 
intervention combined with individualised clinical 
facilitator led support for the management of chronic 
non-malignant pain against the control intervention (self-
help booklet and relaxation compact disc). An embedded 
process evaluation will examine fidelity of delivery and 
investigate experiences of the intervention. The two 
primary outcomes are activities of daily living (measured 
by Patient-Reported Outcomes Measurement Information 
System Pain Interference Short Form (8A)) and opioid use. 
The secondary outcomes are pain severity, quality of life, 
sleep quality, self-efficacy, adverse events and National 
Health Service (NHS) healthcare resource use. Participants 
are followed up at 4, 8 and 12 months, with a primary 
endpoint of 12 months. Between-group differences will 
indicate effectiveness; we are looking for a difference 
of 3.5 points on our pain interference outcome (scale 
40 to 77). We will undertake an NHS perspective cost-
effectiveness analysis using quality adjusted life years.
Ethics and dissemination Full approval was given by 
Yorkshire & The Humber - South Yorkshire Research 
Ethics Committee on 13 September, 2016 (16/YH/0325). 
Appropriate local approvals were sought for each area in 
which recruitment was undertaken. The current protocol 
version is 1.6 date 19 December 2018. Publication of 
results in peer- reviewed journals will inform the scientific 
and clinical community. We will disseminate results 
to patient participants and study facilitators in a study 
newsletter as well as a lay summary of results on the 
study website.
trial registration number ISRCTN49470934; Pre-results.
IntroduCtIon
Chronic pain is defined as pain that persists 
past normal healing time of around 12 
weeks1 2 and affects eight million people 
(15%) in England alone.3 Around 20% of 
those aged 34 years old or over, and around 
40% in those aged 75 years old or over, 
report high levels of interference with their 
lives from pain.3 The common disorders 
contributing to this include low back pain, 
neck pain, osteoarthritis, neuropathic pain, 
fibromyalgia, chronic widespread pain and 
postsurgical pain. Individuals may live with 
more than one of these pain disorders. While 
strengths and limitations of this study
 ► First large multicentre randomised controlled trial 
in UK to test an active intervention (group based 
multicomponent self-management programme plus 
one-to-one support) in comparison to control (self-
help booklet and relaxation compact disc) in opioid 
tapering for those with chronic non-malignant pain.
 ► Recruitment is mainly through primary care, where 
a large population can be screened for use of strong 
opioids.
 ► The intervention is manualised, comprehensive and 
includes a specifically designed app used by the 
clinical facilitators to generate opioid tapering plans.
 ► The embedded process evaluation will help us un-
derstand people’s experiences of the intervention 
and what helped or hindered its use (compared to 
the control group).
 ► The proposed best usual care method is not embed-
ded in current National Health Service practice and 
may thus not represent usual care model.
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opioids are regularly prescribed for the management of 
chronic non-malignant pain, they are not always effec-
tive in the long term and can cause a range of adverse 
effects such as sedation, nausea, respiratory depression/
sleep apnoea, depression, abdominal pain, overdose and 
even death.4 5 Furthermore, people on long-term opioid 
treatment (3 months or more) report inadequate anal-
gesia, in spite of high doses, due to the development of 
tolerance with reduced function, quality of life or absence 
of progress toward therapeutic goals.6–8 Yet, prescription 
data from the UK show that over an 11 year period (2002 
to 2013) there was an increase in prescribing of the more 
potent controlled and long-acting, long-term opioids for 
those with musculoskeletal conditions within the first 90 
days of their long-term episode (2.3% to 9.9%).9 There 
is a pressing need for interventions to help people with-
draw from strong opioids used for chronic non-malignant 
pain.
While much is known about the adverse effects of 
long-term opioid treatment,10 little is known about the 
economical impact of these adverse events. There are 
few evaluations of interventions designed to support 
opioid reduction. Cochrane reviews11 12 and randomised 
controlled trials13 14 offer some support for interventions 
supporting opioid withdrawal, including interdisciplinary 
pain management programmes, use of behavioural 
strategies, motivational interviewing, mindfulness and 
pain education, however, this is of low quality with short 
follow-up (≤4 months).15
There are no formal UK guidelines for opioid reduc-
tion in this population. While such recommendations 
are currently emerging in North America,16 17 these are 
based on expert consensus rather than data. There is 
also no clear evidence to support a particular speed of 
opioid tapering or the use of particular opioid drug(s) 
or rotating from one opioid to another. Overall, data 
substantiating the role of self-management and cognitive 
behavioural interventions in support of opioid tapering is 
weak and mostly applicable to the North American health 
systems.17 Consequently, this trial will test an evidence-
based intervention for people with chronic non-malig-
nant pain. The intervention is designed to help patients 
manage pain interference, reduce individuals’ opioid 
consumption and enhance quality of life.
MEthods/dEsIgn
trial design and objectives
The primary objective is to test the clinical and cost-effec-
tiveness of a patient-centred, group-based, multicompo-
nent, self-management intervention for people living with 
chronic non-malignant pain, compared with a best usual 
care (ie, the control group intervention) in a two-arm 
pragmatic randomised controlled trial (figure 1). The 
intervention targets withdrawal of strong opioids to assess 
the impact of their withdrawal on pain interference with 
daily living. We are running an embedded process evalua-
tion (publication in preparation) to test fidelity to inform 
the interpretation of the findings and, if indicated, impli-
cations for the implementation of the intervention across 
the National Health Service (NHS).
Dates of study enrolment are: 17 May 2017 to 30 January 
2019.
trial setting
The trial is taking place in the North East, East Midlands, 
West Midlands and South Central areas of England. When 
originally planned we also intended to recruit in London. 
However, operational barriers meant we were unable to 
deliver the trial in London. The populations from which 
participants are drawn are broadly representative of the 
UK. We are recruiting participants from general prac-
tices, community pain services, local musculoskeletal 
services and pharmacies. We also accept self-referrals 
(eligibility is checked over the phone once an expression 
of interest form is returned to check study criteria are met 
including non-cancer pain diagnosis and use of strong 
opioids). All medications reported on the baseline ques-
tionnaire are checked again with the participant at time 
to consent. Recruitment sites are clustered by reasonable 
geographical proximity to a treatment site and people in 
one locality are approached accordingly so that the inter-
vention groups can be populated in a timely manner.
For the purpose of this study, we define strong opioids 
using the British National Formulary (BNF). Thus, we 
are recruiting participants taking any of the following 
analgesia: buprenorphine, dipipanone, morphine, 
diamorphine, fentanyl, hydromorphone, methadone, 
oxycodone, papaveretum, pentazocine, pethidine, tapen-
tadol or tramadol.18 Although in some jurisdictions 
tramadol is considered to be a weak opioid the BNF clas-
sifies it as a strong opioid.
recruitment procedures
1. (Primary care) electronic screening of general practitioner (GP) 
records: GP practice lists are searched electronically to 
identify people (aged 18 years or over), who have been 
prescribed strong opioids on more than one occasion 
in the previous 3 to 6 months and in the previous 0 
to 3 months as indicated by their health record and 
not in a care home or housebound. The practice then 
screens the list of those identified from the first search 
to exclude patients taking strong opioids for malignant 
pain or who should not be approached for other rea-
sons, including those at risk, vulnerable or not suitable 
for a group-based intervention. Those who are using 
methadone for purposes other than to manage chron-
ic pain are not approached.
2. Referred to the study by their GP or healthcare professionals at 
pain clinics and musculoskeletal physiotherapy clinics. GPs 
and healthcare professionals at pain clinics and muscu-
loskeletal physiotherapy clinics can also refer potential 
participants by giving them an information pack on 
the study and an expression of interest form.
3. Posters advertising details of the study are displayed in prom-
inent areas of GP surgeries, pharmacies, pain clinics and 
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musculoskeletal physiotherapy clinics. The posters contain 
information about the study, including contact details 
for the study team.
Eligibility and informed consent
Once we receive an expression of interest form from a 
potential participant (with contact details), a member of 
the study team contacts them by telephone to check their 
eligibility for the study, using the inclusion and exclu-
sion criteria as a checklist (table 1). Pregnancy or actively 
trying for pregnancy was included as an exclusion from 
15 November 2018. Following a query from a potential 
participant we identified some evidence, from the addic-
tion literature that abrupt opioid withdrawal may trigger 
miscarriages and stillbirths.19 20 There is no clear evidence 
on how to taper opioids in pregnancy and detoxification 
is not recommended as a treatment intervention due to 
limited evidence available, low completion rates of detox-
ification and high rates of relapse.21
During this telephone check the study team give a 
brief background as to why the study is being done and 
specifically the aims of opioid reduction and study design. 
At this stage of enrolment commitment to opioid dose 
reduction is not mandatory, the aim is to give potential 
participants as much information as possible and answer 
any questions they may have. An anonymised screening 
log is kept, detailing all those screened and reasons for 
exclusion. Potential participants (those who are eligible) 
are then sent a study pack in the post containing an 
I-WOTCH cover letter, participant information sheet, 
trial consent form (online supplementary file), baseline 
questionnaire and pre-addressed envelope. On receipt of 
a signed consent form and completed questionnaire, a 
designated member of the study team performs a final 
telephone eligibility check on medications reported by the 
patient in the baseline questionnaire. If the medications 
meet the eligibility criteria and consent is deemed to be 
valid and informed, the consent form is countersigned by 
the appropriately trained member of the study team and 
a copy of the completed form is sent to the participant 
and to the participant’s GP. Participants are informed 
Figure 1 I-WOTCH flow chart. GP, general practitioner. 
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that if they decline to take part in the study or are found 
to be ineligible there is no impact on their usual form 
of care or access to opioid medication. Where possible, 
participants are randomised in batches of 24 to ensure 
adequate group sizes. Once they are randomised they are 
sent a letter informing them of this with details of the 
group session (time and venue) if they are randomised 
into the intervention arm. There is no further checking 
or consent at this point.
Experimental intervention
I-WOTCH is an 8 to 10 week programme with a mixture 
of group sessions (facilitated by a trained I-WOTCH clin-
ical facilitator, usually a nurse, and a trained lay person 
with chronic pain and experience of opioid tapering, or 
an I-WOTCH trained allied healthcare professional), two 
one-to-one consultations and two telephone calls with the 
I-WOTCH trained clinical facilitator. The programme 
is adapted from a previously tested intervention used 
for the self-management of chronic pain.22 23 All those 
randomised to the I-WOTCH intervention in a locality 
are invited to join Day 1 of the next available programme. 
Should no group be available, or if a participant withdraws 
from the group based intervention, they are sent all of the 
written material that they would have received had they 
attended the group. Attendance at Day 1 is mandatory for 
accessing subsequent elements of the programme.
one-to-one clinical facilitator consultations
Between Day 2 and Day 3 of the group based sessions, 
participants attend a face-to-face, consultation with the 
I-WOTCH trained clinical facilitator. This is an opportu-
nity for the clinical facilitator to explore opioid tapering 
experiences with participants, including thoughts, moti-
vation, perceived challenges and opportunities, and to 
collaboratively develop realistic tapering goals adapted 
to the participant’s circumstances. The clinical facilita-
tors are trained to use motivational interviewing skills to 
facilitate discussion. After Day 3 participants receive two 
telephone consultations (approximately 30 min each) to 
discuss progress with the tapering and to identify the need 
for other support during withdrawal. They also receive 
a final face-to to-face consultation to (i) reflect on prog-
ress, (ii) recap over self-management skills covered in the 
group sessions, (iii) review and reset goals and objectives 
and (iv) assess future needs for support.
I-WOTCH tapering app to generate the opioid tapering plan
We have developed a tapering app to be used by the 
I-WOTCH clinical facilitators in the one-to-one consulta-
tions to generate the tapering plan. The app was devel-
oped within the programming team at Warwick Clinical 
Trials Unit with clinical expertise guided by SE. The app 
facilitates calculations of tapering regimes, as well equian-
algesic doses of systemic opioids when switching between 
opioid preparations is necessary. During our prepara-
tion for the study and design of the app we uncovered a 
discrepancy between a number of existing equianalgesic 
opioid tables24. For the purposes of opioid tapering we 
used the Faculty of Pain Medicine equianalgesic table 
(https://www. rcoa. ac. uk/ faculty- of- pain- medicine/ 
opioids- aware/ structured- approach- to- prescribing/ dose- 
equivalents- and- changing- opioids) for our calculation.25 
We supplemented this with reviews of the individual 
drugs’ summary of product characteristics and other 
sources where needed.26 27 For the purposes of managing 
changes in medication during the taper, individual vari-
ability is taken into account. Once the tapering plan is 
generated a paper copy is given to the participant and 
the electronic data is sent to the study team for checking 
and filing. All tapering plans generated are checked by a 
clinician for accuracy (SE or JN). A paper copy is sent to 
the participant’s GP for their records.
opioid tapering procedures
Participants are tapered on their drug of presentation. 
Opioid rotation is only recommended for participants 
who have reached the lowest dose of a transdermal 
patch preparation. For example, in cases of participants 
presenting on fentanyl transdermal patches these are 
tapered in decrement of 12 mcg/hour patches, and an 
oral formulation of alternative opioid with equianalgesic 
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
 ► Provision of written informed consent
 ► Aged 18 years old or above
 ► Using opioids for chronic non-malignant pain
 ► Using strong opioids for at least 3 months
 ► Using strong opioids on most days in the preceding month
 ► Fluent in written and spoken English
 ► Able to attend group sessions
 ► Willingness for GP to be informed of participation
 ► Regular use of injected opioid drugs
 ► Chronic headache as the dominant painful disorder
 ► Serious mental health problems that preclude participation 
in a group intervention
 ► Previous entry or randomisation in the present trial
 ► Participation in a clinical trial of an investigational medicinal 
product in the last 90 days
 ► Pregnant at time of eligibility assessment, or actively trying 
to become pregnant.*
 ► People receiving strong opioid for the management of pain 
due to active malignant disease
*Added as exclusion criteria from 15 November 2018.
GP, general practitioner. 
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potency introduced when the lowest increment of the 
patch is reached.28 Participants on buprenorphine 
patches are weaned in decrements of the patches with 
no substitution due to its agonist/antagonist action.29 
The nurses make every effort to encourage participants 
to stick to the suggested tapering schedule. Nevertheless, 
there is an element of negotiation about speed, if any, of 
dose reduction.
We are using a regimen based on the Mayo Clinic 
experience as it provides some evidence to support the 
notion of slow tapering and is unlikely to be associated 
with severe withdrawal symptoms and therefore likely to 
facilitate adherence.28 This consists of a 10% decrease of 
the original dose every 5 to 7 days until 30% of the orig-
inal dose is reached. This is followed by a weekly decrease 
by 10% of the remaining dose. The 10% may be rounded 
up or down to suit prescribing. We are providing training 
in equianalgesic dose calculation as well as an electronic 
means of calculating. People utilising opioids as rescue 
analgesia, at a frequency of less than one dose per day, do 
not require a formal tapering regime but are still being 
supported to completely withdraw from opioids.
Facilitator training
I-WOTCH facilitators (clinical and lay) attend a 2-day 
training course delivered by HS and JS (experienced in 
the design and delivery of the intervention) to deliver the 
intervention. Over the 2 days the facilitators are taught 
how to deliver each of the topics, as well as given an oppor-
tunity to experience the mindfulness and relaxation prac-
tice which is a part of the programme. In addition they 
are also taught group facilitation skills and procedures to 
follow within the study. The I-WOTCH clinical facilitators 
also attend a third day of training, during which they are 
given further opioid education, and trained in how to 
taper, use of the I-WOTCH app, motivational interviewing 
and study procedures for the one-to-one consultations.
We have adapted a comprehensive facilitator’s manual 
and training programme used in a previous trial on the 
management of chronic pain23 to facilitate delivery of 
the I-WOTCH intervention (in preparation). The adap-
tations have been formed through literature, piloting of 
the intervention and input from lay people (those with 
chronic pain and experience of opioid use). The manual 
is acting as a guide and a reference point for all facilita-
tors throughout the intervention.
Adaptations and development of the intervention has 
included: structuring the programme to include opioid 
education as well as pain education, and integrating these 
throughout the programme. Specific examples and case 
studies related to opioid tapering and pain have been 
used, mindfulness and relaxation compact discs (CDs) 
created and a video (focused on pain and opioid educa-
tion) has been produced for participants. Clips of the 
video are integrated into the group programme to illus-
trate specific topics such as pain education, challenging 
unhelpful thoughts and fear related to opioid tapering 
and withdrawal. Participants are given the full video on 
a digital versatile disc (DVD) to watch with their friends 
and family. Having the DVD allows the participant to 
watch it in their own time and consolidate the informa-
tion learnt on the programme. Specially designed hand-
outs are given to participants at the end of each group day 
summarising key topics discussed. Further details of the 
intervention and its theoretical framework used to design 
are to be reported elsewhere.
Control intervention
Those randomised to the control group will receive 
augmented usual care, including two participant-facing 
components: a hard copy of the I-WOTCH adapted 
‘My Opioid Manager’ booklet, and a relaxation CD 
with instructions on its use. ‘My Opioid Manager’ was 
developed in Canada (Toronto Rehabilitation Institute) 
specifically for people using opioid drugs for chronic 
non-cancer pain. It is a self-help guide that contains infor-
mation about opioids and provides guidance about setting 
goals, issues the participant may encounter, tapering and 
non-opioid options for management of chronic pain. It is 
based on the 2010 Canadian Opioid guideline of opioids 
for chronic non-cancer pain.30
Compliance
For the intervention, we are recording the number of 
sessions that each participant attends, including the 
follow-up calls completed. Assurance checks through the 
study also include the integrity of randomisation, study 
entry procedures and data collection.
study outcomes
Primary outcome: activities of daily living
Our primary clinical outcome is the Patient-Reported 
Outcomes Measurement Information System (PROMIS) 
Pain Interference Short Form (8A) (PROMIS-PI-SF-8A).31 
This is an eight-item generic self-reported measure, which 
assesses the consequences of pain on relevant aspects 
of an individual’s life and key activities of daily living: 
engagement with social, cognitive, emotional, physical 
and recreational practices. The PROMIS-PI-SF-8A raw 
score ranges from 4 to 80 which is then standardised to 
give a score ranging from 40.7 to 77, with higher scores 
indicating worse outcome. The PROMIS-PI measures the 
same construct as two legacy pain interference measures 
(Brief Pain Inventory Pain Interference subscale and the 
SF-36 Bodily Pain subscale), supporting the calculation of 
a common metric.32 33
As originally designed, we proposed pain interference 
as a single primary outcome to ensure we could recruit 
sufficient participants. However, how the intervention 
might affect pain interference  directly through its 
behavioural and educational component and how there 
might be indirect effects through changing opioid use 
is unclear. It is possible, for example, that the interven-
tion has a good effect on opioid use but little effect on 
pain interference. In this situation the potential long-
term benefits of opioid reduction might justify claiming 
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a positive result from the trial. During the later stages of 
recruitment, it became clear we had capacity, and suffi-
cient interest from practices and potential participants to 
exceed our planned target. This allowed us to add opioid 
use as a prespecified second primary outcome.
Our main outcome measure for opioid use is the mean 
difference in morphine equivalent dose in the 4 weeks 
prior to 1 year follow-up expressed as mg equivalents of 
morphine per day. In ongoing work we are reviewing 
morphine equivalence tables before making a final deci-
sion on which set of equivalence values to use for this 
analysis. For sensitivity analyses, we will use alternative 
published values for equianalgesic doses of opioids to 
ensure that our findings are robust if different weight-
ings are used. For secondary analyses, we are comparing 
proportions achieving a complete withdrawal and 
proportions of responders, defined as ≥50% reduction in 
morphine equivalent doses taken, between intervention 
and control groups.
While our study entry criterion is participant reported 
use of strong opioids on most days in the preceding 
4 weeks, our continuous measure of opioid use is mean 
morphine equivalents of opioid used in the preceding 
4 weeks. This includes all opioids consumed, including 
any weak or as required opioids.
Self-reported data on opioid use are being collected 
at baseline, 4, 8 and 12 months following randomisation 
via postal follow-up. At baseline, one postal reminder is 
sent. At 4, 8 and 12 months a postal reminder is sent. In 
the event that no response is obtained from the postal 
reminder at 4, 8 or 12 months, we contact the partici-
pant by phone and collect our primary clinical outcome, 
opioid use and EQ-5D-5L34 over the phone. Participants 
complete a weekly diary that includes the EQ-5D-5L34 and 
the Short Opiate Withdrawal Scale35 for the first 4 months 
after randomisation.
secondary outcomes
Our package of other secondary outcomes and process 
measures is informed by the consensus recommenda-
tions for core outcome domains for trials of the efficacy 
and effectiveness of treatments for chronic pain by the 
Initiative on Methods, Measurement and Pain Assess-
ment in Clinical Trials group.36 All outcome measures are 
presented in table 2 with data collection time points.
Power and sample size
For the purposes of our original sample size calcula-
tion we used our primary clinical outcome measure, 
the PROMIS-PI-SF-8A.31 Using the PROMIS primary 
outcome, participants in the control arm are likely to 
obtain a mean score of 50, SD 10.37 A sample size of 346 
participants is required to show a difference of 3.5 points 
on PROMIS-PI-SF-8A (standardised mean difference of 
0.35) at 5% significance with 90% power. There may, 
however, be clustering effects by groups in the interven-
tion arm. We do not have any data from similar studies to 
inform an estimate of the intracluster correlation (ICC). 
Our recent experience across multiple studies of group 
interventions has been that such effects are trivial or negli-
gible.22 38 39 Despite this, assuming a relatively modest ICC 
of 0.01 and assuming, on average, that 10 participants 
per group provide 1 year outcome data, we would require 
374 patients. Allowing for 20% loss to follow-up (while 
Table 2 Outcomes measures and time points
Outcome measure Baseline 4 months 8 months 12 months
Demographic data x
PROMIS pain interference short form (8A)31 x x x x
Self-reported opioid use (mean morphine equivalents of opioid 
used in the preceding 4 weeks)
x x x x
Opioid prescription from GP records x
EQ-5D-5L34 x x x x
SF-12 V246 x x x x
Short opiate withdrawal scale35 x x x x
PROMIS pain intensity short form (3A)32 33 x x x x
Pittsburgh sleep quality index47 x x x x
Hospital anxiety and depression scale48 x x x x
Pain self efficacy questionnaire49 x x x x
Participant ratings of global improvement and satisfaction 
with treatment
Patient global impression of change
x x x x
Symptoms and adverse events
Passive capture of spontaneously reported adverse events and 
symptoms and use of open-ended prompts
x x x x
GP, general practitioner; PROMIS, Patient-Reported Outcomes Measurement Information System. 
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striving for 10%) we planned to recruit 468 participants. 
We subsequently changed the significance level to 2.5% 
to allow for two primary outcomes (PROMIS-PI-SF-8A 
and opioid use) with effect size of similar magnitude, and 
adjusted the inflation factor for clustering to reflect actual 
group sizes. Our final recruitment target was 542 partic-
ipants. Experience in similar studies is that, towards the 
end of recruitment, there can be a need to over-recruit 
slightly more people than originally projected to ensure 
the final intervention groups are adequately populated.
randomisation methods and blinding procedures
Patients are randomised in a 1:1 ratio to either the 
I-WOTCH intervention or best usual care arms. Rando-
misation procedures are being performed at the Warwick 
Clinical Trials Unit (WCTU) where possible randomisa-
tions are carried out by a member of staff who is not a core 
member of the I-WOTCH team. The method of randomi-
sation is computer generated using WCTU randomisation 
systems developed by the WCTU programmers. There 
is no allocation concealment as the person conducting 
the randomisation is also entering baseline data prior to 
randomisation. All baseline data are being collected prior 
to randomisation. Where possible any data collected from 
GP records is being done by staff blind to treatment allo-
cation. Routine data sources such as GP prescribing data 
are also collected.
To ensure that we populate the groups, we are clustering 
groups of four to five geographically proximate practices 
with approximately 50 000 patients to launch recruitment 
at around the same time. We are then randomising partic-
ipants when we have sufficient participants to populate 
a group in batches of around 24 participants to mini-
mise time between randomisation and the start of the 
intervention. We aim to randomise within 2 weeks of the 
start of the group. This ensures exposure time to the 
two interventions is as similar as possible. We anticipate 
the number of people in a group to between 10 and 12 
participants. However due to the pragmatic nature of the 
trial and the possibility that participants may not turn up 
on the day of the group, we will run the group with a 
minimum of two people. We will record attendance and 
the number of people in each group for each day. Rando-
misation has been stratified by group (Groups 1 to 35), 
baseline pain severity (PROMIS 3A score: low pain=3 to 8, 
high pain=9 to 15) and baseline opioid use (morphine 
equivalent dose: 0 to 29, 30 to 59, 60 to 89, 90 to 119, 
120 to 149, 150+).
data management
Data for individual participants are being collected via 
participant-completed questionnaires, by clinical facil-
itator-completed case report forms (CRF), or by collec-
tion from participants’ GP records by a member of 
the I-WOTCH research team or local clinical research 
network support team.
Participant identification in the CRF is done through 
their initials and unique research number allocated at the 
point of entering into the study. Data are being collected 
from the time the potential participant is considered for 
entry into the research through to completion of the inter-
vention and follow-up period (interviews are conducted 
after the 12 month follow-up). Data are subject to a full 
set of validation checks and additional data checking 
procedures to assure quality of data entry.
All (paper) data are being held securely by the research 
team at WCTU for the baseline questionnaires, inter-
vention evaluation sheets, postal questionnaires at 4, 
8 and 12 months, weekly diary booklets and any ad hoc 
CRFs required. The database has been developed by the 
programming team at WCTU and all specifications (ie, 
database variables, validation checks, screens) have been 
agreed between the programmer and appropriate trial 
staff including the trial statistician.
All essential documentation and trial records are being 
stored by WCTU in conformance with the applicable 
regulatory requirements. Access to stored information is 
restricted to authorised personnel only.
We developed questionnaires to record relevant infor-
mation. CRFs have been designed by research fellows and 
the trial manager in conjunction with our trial manage-
ment group (TMG) building on the expertise of the 
applicants. The TMG consists of project staff and co-in-
vestigators involved in the running of the day-to-day trial. 
Significant issues arising from management meetings are 
referred to the Group.
The trial steering committee (TSC) has an independent 
chairperson. The Committee is responsible for major 
decisions such as a need to change the protocol for any 
reason, monitoring and supervising the progress of the 
trial, reviewing relevant information from other sources, 
considering recommendations from the Committee and 
informing and advising on all aspects of the trial.
The data monitoring committee (DMC) consists of 
independent experts with relevant clinical research and 
statistical experience. Confidential reports containing 
recruitment, protocol compliance, safety data and interim 
assessments of outcomes are being reviewed by the 
Committee. The DMC is responsible for monitoring data 
and making recommendations to the TSC on whether 
there are any ethical or safety reasons why the trial should 
be amended or terminated. The DMC will determine if 
additional interim analyses of trial data should be under-
taken, and if so, when. The DMC will meet early on in the 
trial and then annually or more frequently if necessary. 
The final DMC meeting will be held on the availability of 
the final trial data.
Both the trial steering committee and the data moni-
toring committee follow WCTU standard operating 
procedures.
All electronic participant-identifiable information are 
held on a secure, password-protected database accessible 
only to essential personnel. Paper forms with partici-
pant-identifiable information are held in secure, locked 
filing cabinets within a restricted area of WCTU. Partic-
ipants are identified by a unique research number only. 
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Direct access to source data/documents is required for 
trial-related monitoring. For quality assurance, the data 
and results are statistically checked. A full data manage-
ment plan has been produced by the trial manager 
and statistician to outline the data monitoring checks 
required. Trial documentation and data will be archived 
for at least 10 years after completion of the trial.
Adverse event management
Any adverse events are reported to the trial coordinating 
centre by the clinical facilitators in each region within 
24 hours of them becoming aware of the event. Partici-
pants will be asked if they have experienced any adverse 
effects while tapering opioid use at the clinical facilitator 
consultations, in the weekly diaries and in question-
naire follow-up at 4, 8 and 12 months; and if so, which 
symptoms they have experienced. Participants GP’s will 
not be informed of any adverse events unless there are 
serious safety concerns and there is a chance of signif-
icant harm to the participant or others. In accordance 
with WCTU standard operating procedures risk assess-
ment is completed and a trial monitoring plan produced 
commensurate to the risks identified.
statistical analysis
The data will be summarised and reported in accordance 
with Consolidated Standards of Reporting Trials guidelines 
for randomised controlled trials. We are using intention-
to-treat analyses.40 Hierarchical linear regression models 
are used to estimate the treatment effects (with 95% CIs), 
and are adjusted for important patient-level covariates. 
These will be defined in the final approved statistical anal-
ysis plan which will include specific methods of analysis 
for all outcome variables. We have included estimation 
of and adjustment for group effects. If there is negligible 
group effect, then the usual linear regression will be 
used for the analysis. Any categorical data is assessed in a 
similar way, using logistic regression models. Prespecified 
subgroup analyses examine the interaction of treatment 
assignment with symptoms of anxiety/depression and 
baseline opioid use. Analysis is conducted using formal 
tests of interaction.41 This trial is not powered to iden-
tify interactions. Thus, while prespecified, these analyses 
should be considered as no more than exploratory. We 
are exploring the extent to which change in opioid use, 
or changes in self-efficacy, mediate change in activities of 
daily living to gain some understanding as to whether any 
effects seen are the non-specific effects of the behavioural 
component of the intervention or they are specifically 
due to change in opioid usage.
health economic evaluation
Published evidence and data from the COping with 
persistent Pain, Effectiveness Research in Self-manage-
ment (COPERS) study,23 informed the process of concep-
tualising the structure of a decision analytic model 
— representing the treatment pathway of individual’s on 
long-term opioid therapy for non-malignant chronic pain. 
Data requirements to populate our model structure were 
used to inform the data collection strategy of the main 
I-WOTCH trial. The economic analysis of the I-WOTCH 
study will be in three stages. First, published evidence and 
individual patient level data from the I-WOTCH internal 
pilot and COPERS studies will be used to populate the 
model structure and conduct a Bayesian value of infor-
mation analysis to identify those parameters for which 
additional data collection is warranted. Second, we will 
conduct a within-trial cost-consequences analysis from 
the perspective of the NHS and social services. Third, a 
model-based cost-utility analysis will be conducted to esti-
mate the long-term cost-effectiveness of the I-WOTCH 
intervention versus best usual care. This comprehen-
sive iterative approach has been tested and successfully 
implemented by one of the applicants in the context of a 
number of previous National Institute Health Research42 
and Medical Research Council (MRC) funded studies.43 44
Process evaluation and intervention fidelity
The process evaluation will investigate any barriers and 
enablers to the intervention recommendations becoming 
part of everyday behaviour patterns, from both the 
perspective of those delivering and receiving the inter-
vention. We will collect observational data by digitally 
audio-recording all intervention interactions. We will 
analyse 10% of the recordings to assess fidelity to protocol 
and further investigate interaction between facilitators 
and participants. Process evaluation includes outcomes 
around motivation, expectation and confidence in ability 
to reduce opioids.
We will conduct semi-structured interviews with 
approximately 20 participants in the intervention and 20 
in the control arms. To ensure a diverse range of views, 
participants will be selected purposively by age, gender, 
geographical location, baseline and follow-up opioid use. 
We will also undertake interviews with a sample of staff 
delivering the intervention about their experiences of 
teaching it including enablers and barriers. More infor-
mation can be found in the protocol for the process 
evaluation.45
End of trial
The end of the trial is defined as the date when the last 
participant completes their 12 month follow-up after 
randomisation. However, follow-up data collection will 
proceed beyond this date, in particular interviews with 
participants contributing to the process evaluation.
Patient and public involvement
Two lay advisers with chronic pain, withdrawal of opioids 
and substantive experience of clinical trial research have 
been fully involved in the development of the study and 
intervention. One remains an active member of the study 
team (CT), the other took retirement from her role 
during the study (SB). Both lay advisors were recruited 
via Universities/User Teaching and Research Action Part-
nership (UNTRAP).
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Additionally, prior to receiving funding for the study we 
ran two meetings at the North East and North Cumbria 
Clinical Research Network. The meetings included volun-
teers (n=19) who were people living with chronic non-ma-
lignant pain, some of whom had discontinued opioids 
without medical supervision, others who had discontinued 
with GP or pain clinic supervision. Both events allowed 
discussion and input into the design of the intervention 
structure; (group days and one-to-one support) length 
of the intervention and content to be covered based on 
education, motivation, support and providing alternative 
pain management techniques. The meetings also allowed 
discussion of the design of the study which included 
randomisation, best usual care intervention, recruitment 
processes as well as outcome measures to collect. Patient 
and public involvement (PPI) participants did not feel 
the intervention or outcome measures were burdensome 
and welcomed both arms of the intervention as support 
for opioid tapering. They also supported the idea of 
having a lay person with chronic pain with experience of 
opioid withdrawal to deliver the group days in the active 
intervention alongside a clinician. In addition to the PPI 
events, and again prior to receiving funding for the study, 
we were able to pilot the facilitator training and delivery 
of the I-WOTCH intervention as part of the Hambleton 
and Richmond, clinical commissioning group funded 
community pain service in the North East. This allowed 
feedback into what worked well and recommendations 
for changes and improvements.
We will disseminate findings of the main study for the 
patient participants and group facilitators through a study 
newsletter and post a lay summary on the study website. In 
partnership with our PPI representatives we will also feed-
back to the organisations they represent such as UNTRAP 
and the PPI events as part of the North East and North 
Cumbria Clinical Research Network.
EthICs And dIssEMInAtIon
The University of Warwick (Research Impact Services, 
University of Warwick, Coventry CV4 7AL) is the Sponsor 
for the study. The study is being conducted in full adher-
ence with the principles of the Declaration of Helsinki 
and MRC Good Clinical Practice principles and guide-
lines. It also complies with all applicable UK legislation 
and Warwick Standard Operating Procedures. All data 
are being stored securely and held in accordance with 
the Data Protection Act 2018. All identifiable data are 
pseudo-anonymised and treated as confidential. Patients 
have the choice of whether or not to participate and are 
given all relevant information about the study to make 
an informed decision. Participants are informed that they 
are free to withdraw from the trial at any time during any 
phase of the work without providing a reason and without 
prejudice, if they so wish. The findings will be dissemi-
nated in peer-reviewed journals. We will also publish 
results on the study website and produce a newsletter 
for the study facilitators and patient participants. We will 
engage with NHS organisations, managers, policymakers 
and clinical commissioning groups to ensure effective 
dissemination of the findings and inform national, and 
international, guidance on opioid reduction in this popu-
lation. Appropriate local approvals were sought for each 
area in which recruitment was undertaken. The trial is 
being co-ordinated by the WCTU, University of Warwick.
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